The securities litigation law firm of Brower Piven, A Professional
Corporation, has commenced an investigation into possible breaches of
fiduciary duty and other violations of state law by the Board of
Directors of Ambit...
Former United States Securities and Exchange Commission attorney Willie
Briscoe and the securities litigation firm of Powers
Taylor LLP are investigating potential claims against the Board of
Directors of Ambit Biosciences...
Japanese pharmaceutical major Daiichi Sankyo Co. is buying the smaller, U.S.-based biopharma concern Ambit Biosciences Corp. for approximately $315 million in cash, the two companies said Sunday in a joint statement. The $15-a-share price...
Daiichi Sankyo, Japan's second-largest pharma outfit, has agreed to pay up to $650 million to get its hands on some hydrocodone combo medications, striking a deal with Charleston Laboratories with hopes of cashing in on the demand for pain pills.
Once again the FDA has reached a conclusion that is directly opposed by some of its own scientists. Last month the FDA affirmed the safety of olmesartan, a popular blood pressure lowering drug (sold as Benicar and other names). But that...
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Portola+Pharma+%28PTLA%29%2C+Daiichi+Sankyo+Enter+Second+Clincial+Collaboration+for+Andexanet+Alfa/9641858.html for the full story.
After four years of sifting data, the FDA says it found "no clear evidence" that Daiichi Sankyo's blockbuster blood pressure drug increased the risk of heart attack. But the agency will require new safety-related data on Benicar's official label.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Daiichi Sankyo Company (4568-TO):